|
1
|
Azegami T, Sasamura H, Hayashi K and Itoh
H: Vaccination against the angiotensin type 1 receptor for the
prevention of L-NAME-induced nephropathy. Hypertens Res.
35:492–499. 2012. View Article : Google Scholar
|
|
2
|
Hill GS: Hypertensive nephrosclerosis.
Curr Opin Nephrol Hypertens. 17:266–270. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang S, Li H, Li Y, et al: Nicousamide
normalizes renovascular hypertension in two-kidney one-clip
hypertensive rats. Biomed Rep. 1:89–92. 2013.PubMed/NCBI
|
|
4
|
Zhang S, Li Y, Li H, et al: Renal
protective effect of nicousamide on hypertensive nephropathy in
spontaneously hypertensive rats. Biomed Rep. 1:34–40.
2013.PubMed/NCBI
|
|
5
|
Iseki K: Factors influencing the
development of end-stage renal disease. Clin Exp Nephrol. 9:5–14.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Klag MJ, Whelton PK, Randall BL, et al:
Blood pressure and end-stage renal disease in men. N Engl J Med.
334:13–18. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tozawa M, Iseki K, Iseki C, Kinjo K,
Ikemiya Y and Takishita S: Blood pressure predicts risk of
developing end-stage renal disease in men and women. Hypertension.
41:1341–1345. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen Y, Lipkowitz MS, Salem RM, et al:
Progression of chronic kidney disease: Adrenergic genetic influence
on glomerular filtration rate decline in hypertensive
nephrosclerosis. Am J Nephrol. 32:23–30. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang G, Lai FM, Kwan BC, et al: Expression
of ACE and ACE2 in patients with hypertensive nephrosclerosis.
Kidney Blood Press Res. 34:141–149. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Moghadam MH, Imenshahidi M and Mohajeri
SA: Antihypertensive effect of celery seed on rat blood pressure in
chronic administration. J Med Food. 16:558–563. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang L, Lü L, Chan WM, et al: Effects of
DL-3-n-butylphthalide on vascular dementia and angiogenesis.
Neurochem Res. 37:911–919. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liao SJ, Lin JW, Pei Z, et al: Enhanced
angiogenesis with dl-3n-butylphthalide treatment after focal
cerebral ischemia in RHRSP. Brain Res. 1289:69–78. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chong ZZ and Feng YP:
dl-3-n-butylphthalide attenuates reperfusion-induced blood-brain
barrier damage after focal cerebral ischemia in rats. Zhongguo Yao
Li Xue Bao. 20:696–700. 1999.
|
|
14
|
Cui LY, Zhu YC, Gao S, et al: Ninety-day
administration of dl-3-n-butylphthalide for acute ischemic stroke:
a randomized, double-blind trial. Chinese Med J (Engl).
126:3405–3410. 2013.
|
|
15
|
Li L, Zhang B, Tao Y, et al:
DL-3-n-butylphthalide protects endothelial cells against
oxidative/nitrosative stress, mitochondrial damage and subsequent
cell death after oxygen glucose deprivation in vitro. Brain Res.
1290:91–101. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu CL, Liao SJ, Zeng JS, et al:
dl-3n-butylphthalide prevents stroke via improvement of cerebral
microvessels in RHRSP. J Neurol Sci. 260:106–113. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tian D, Ling S, Chen G, et al:
Hypertensive nephropathy treatment by heart-protecting musk pill: a
study of anti-inflammatory therapy for target organ damage of
hypertension. Int J Gen Med. 4:131–139. 2011.PubMed/NCBI
|
|
18
|
Sun L, Ke Y, Zhu CY, et al: Inflammatory
reaction versus endogenous peroxisome proliferator-activated
receptors expression, re-exploring secondary organ complications of
spontaneously hypertensive rats. Chin Med J (Engl). 121:2305–2311.
2008.
|
|
19
|
Koshikawa S, Nishikimi T, Inaba C, et al:
Fasudil, a Rho-kinase inhibitor, reverses L-NAME exacerbated severe
nephrosclerosis in spontaneously hypertensive rats. J Hypertens.
26:1837–1848. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Alfie J, Aparicio LS and Waisman GD:
Current strategies to achieve further cardiac and renal protection
through enhanced renin-angiotensin-aldosterone system inhibition.
Rev Recent Clin Trials. 6:134–146. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Berl T: Review: renal protection by
inhibition of the renin-angiotensin-aldosterone system. J Renin
Angiotensin Aldosterone Syst. 10:1–8. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang S, Xin H, Li Y, et al: Skimmin, a
coumarin from Hydrangea paniculata, slows down the progression of
membranous glomerulonephritis by anti-inflammatory effects and
inhibiting immune complex deposition. Evid Based Complement
Alternat Med. 8192962013.PubMed/NCBI
|
|
23
|
Tapia E, Sanchez-Lozada LG, Soto V, et al:
Sildenafil treatment prevents glomerular hypertension and
hyperfiltration in rats with renal ablation. Kidney Blood Press
Res. 35:273–280. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pörsti I, Fan M, Kööbi P, et al: High
calcium diet down-regulates kidney angiotensin-converting enzyme in
experimental renal failure. Kidney Int. 66:2155–2166. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li P, Ma LL, Xie RJ, et al: Treatment of
5/6 nephrectomy rats with sulodexide: a novel therapy for chronic
renal failure. Acta Pharmacol Sin. 33:644–651. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Giani JF, Muñoz MC, Pons RA, et al:
Angiotensin-(1–7) reduces proteinuria and diminishes structural
damage in renal tissue of stroke-prone spontaneously hypertensive
rats. Am J Physiol Renal Physiol. 300:F272–F282. 2011. View Article : Google Scholar
|
|
27
|
Tomohiro T, Kumai T, Sato T, et al:
Hypertension aggravates glomerular dysfunction with oxidative
stress in a rat model of diabetic nephropathy. Life Sci.
80:1364–1372. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li L, Yang R, Sun K, et al: Cerebroside-A
provides potent neuroprotection after cerebral ischaemia through
reducing glutamate release and Ca2+ influx of NMDA
receptors. Int J Neuropsychopharmacol. 15:497–507. 2012. View Article : Google Scholar
|
|
29
|
Liu Y: Renal fibrosis: new insights into
the pathogenesis and therapeutics. Kidney Int. 69:213–217. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tomino Y, Hagiwara S and Gohda T: AGE-RAGE
interaction and oxidative stress in obesity-related renal
dysfunction. Kidney Int. 80:133–135. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Koyner JL, Sher Ali R and Murray PT:
Antioxidants. Do they have a place in the prevention or therapy of
acute kidney injury? Nephron Exp Nephrol. 109:e109–e117. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Semedo P, Correa-Costa M, Antonio Cenedeze
M, et al: Mesenchymal stem cells attenuate renal fibrosis through
immune modulation and remodeling properties in a rat remnant kidney
model. Stem Cells. 27:3063–3073. 2009.PubMed/NCBI
|
|
33
|
Azuma H, Nadeau K, Takada M, Mackenzie HS
and Tilney NL: Cellular and molecular predictors of chronic renal
dysfunction after initial ischemia/reperfusion injury of a single
kidney. Transplantation. 64:190–197. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Navarro-González JF and Mora-Fernández C:
The role of inflammatory cytokines in diabetic nephropathy. J Am
Soc Nephrol. 19:433–442. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cervenka L and Heller J: Comparison of the
effects of a low-protein diet with the effects of a converting
enzyme inhibitor on the progression of renal insufficiency in
hypertensive rats. Renal Fail. 18:173–180. 1996. View Article : Google Scholar
|
